Abstract A010: Using oncogenic pathway agonism to sensitize RAS-mutant cancers to immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a010
Abstract: Overall, some 30% of human cancers are driven by mutant RAS proteins, which have proven relatively difficult to target. While immunotherapy is effective for NRAS-mutant melanoma, no options exist for resistant disease, and mutant KRAS-driven… read more here.
Keywords: oncogenic pathway; ras mutant; sensitize ras; pathway agonism ... See more keywords